Mohamed-Reda Benmebarek
Overview
Explore the profile of Mohamed-Reda Benmebarek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Seifert M, Benmebarek M, Briukhovetska D, Markl F, Dorr J, Cadilha B, et al.
Br J Cancer
. 2022 Oct;
127(12):2175-2185.
PMID: 36266575
Background: Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a...
12.
Stock S, Benmebarek M, Kluever A, Darowski D, Jost C, Stubenrauch K, et al.
J Immunother Cancer
. 2022 Jul;
10(7).
PMID: 35902133
Background: Chimeric antigen receptor (CAR) T cell therapy has proven its clinical utility in hematological malignancies. Optimization is still required for its application in solid tumors. Here, the lack of...
13.
Bashiri Dezfouli A, Yazdi M, Benmebarek M, Schwab M, Michaelides S, Micciche A, et al.
Front Immunol
. 2022 Jun;
13:883694.
PMID: 35720311
Strategies to boost anti-tumor immunity are urgently needed to treat therapy-resistant late-stage cancers, including colorectal cancers (CRCs). Cytokine stimulation and genetic modifications with chimeric antigen receptors (CAR) represent promising strategies...
14.
Darwich A, Silvestri A, Benmebarek M, Mouries J, Cadilha B, Melacarne A, et al.
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34824159
Background: Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical...
15.
Cadilha B, Benmebarek M, Dorman K, Oner A, Lorenzini T, Obeck H, et al.
Sci Adv
. 2021 Jun;
7(24).
PMID: 34108220
CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (T) cells suppress the immune response...
16.
Blaeschke F, Stenger D, Apfelbeck A, Cadilha B, Benmebarek M, Mahdawi J, et al.
Blood Cancer J
. 2021 Jun;
11(6):108.
PMID: 34088894
No abstract available.
17.
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, et al.
Nat Biomed Eng
. 2021 Jun;
5(11):1246-1260.
PMID: 34083764
The efficacy of adoptive cell therapy for solid tumours is hampered by the poor accumulation of the transferred T cells in tumour tissue. Here, we show that forced expression of...
18.
Schwerdtfeger M, Benmebarek M, Endres S, Subklewe M, Desiderio V, Kobold S
Curr Hematol Malig Rep
. 2021 May;
16(2):218-233.
PMID: 33939108
Purpose Of Review: Both chimeric antigen receptor (CAR) T cells and T cell-engaging antibodies (BiAb) have been approved for the treatment of hematological malignancies. However, despite targeting the same antigen,...
19.
Benmebarek M, Cadilha B, Herrmann M, Lesch S, Schmitt S, Stoiber S, et al.
Leukemia
. 2021 Jan;
35(8):2243-2257.
PMID: 33414484
Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia...
20.
Lesch S, Benmebarek M, Cadilha B, Stoiber S, Subklewe M, Endres S, et al.
Semin Cancer Biol
. 2019 Nov;
65:80-90.
PMID: 31705998
The remarkable success of chimeric antigen receptor (CAR)-engineered T cells in pre-B cell acute lymphoblastic leukemia (ALL) and B cell lymphoma led to the approval of anti-CD19 CAR T cells...